Pneumococcal 13-valent vaccine, diphtheria conjugate Intramuscular and Selegiline Hydrochloride

• Generic Name: pneumococcal 13-valent vaccine
• Dosage Forms: n.a.
• Other Brand Names: Prevnar 13

Pneumococcal 13-valent diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by pneumococcal bacteria. It works by causing your body to produce its own protection (antibodies) against the disease.

Pneumococcal infection can cause serious problems, such as pneumonia, which affects the lungs; meningitis, which affects the brain; and bacteremia, which is a severe infection in the blood. Pneumococcal infection is also an important cause of ear infections in children.

Unless otherwise contraindicated, immunization (vaccination) against pneumococcal disease is recommended for infants and young children 6 weeks to 5 years of age (prior to the 6th birthday), children 6 to 17 years of age (prior to the 18th birthday), or to adults 18 years of age and older.

For infants and young children, immunization requires 1 to 4 doses of the vaccine, depending on the age at the first dose. This vaccine can be given at the same time as other routine vaccinations.

This vaccine is to be given only by or under the supervision of your doctor.

• Generic Name: selegiline
• Dosage Forms: n.a.
• Other Brand Names: Eldepryl, Zelapar, Emsam

Used as adjunctive therapy for symptomatic treatment of parkinsonian syndrome (e.g., parkinsonism, Parkinson disease [paralysis agitans]) in patients who exhibit a deteriorating response to levodopa/carbidopa; designated an orphan drug by FDA for this condition. Appears to be most beneficial when used during the early stages of the “wearing off” effect. Especially useful in improving “end-of-dose” motor fluctuations.

Has been used as monotherapy in patients with newly diagnosed parkinsonian syndrome. Because selegiline is well tolerated and possibly neuroprotective (i.e., reduces the rate of progression of parkinsonian syndrome ), some clinicians initiate therapy with selegiline in such patients, reserving levodopa or another agent (i.e., dopamine agonist) until manifestations become severe enough to warrant more aggressive therapy. However, the manufacturers state that there is no evidence from controlled studies indicating that selegiline provides benefit in the absence of concurrent levodopa therapy.

Has been used with equivocal results for the palliative treatment of mild to moderate dementia of the Alzheimer’s type (Alzheimer’s disease, presenile or senile dementia).